Targeted drug trial for tough breast cancer type
NCT ID NCT03130439
Summary
This study tested whether the drug abemaciclib could help control advanced triple-negative breast cancer that had spread to other parts of the body. Researchers enrolled 27 patients whose cancer tested positive for a specific protein called Rb. The trial was terminated early, and the drug was not yet approved for this type of cancer at the time of the study.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.